Mutations within a conservative region of HCV affects the therapy

At least 200 million individuals are currently infected with hepatitis C virus (HCV) worldwide. Approximately 30%-50% of patients respond to interferon/ribavirin combination therapy. Response to interferon therapy depends mainly on viral and host genetic factors. The HCV is continually mutating which allows the virus to evade the immune system and overcome interferon treatment.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news157632931.html">Mutations within a conservative region of HCV affects the therapy</a></p> <p>At least 200 million individuals are currently infected with hepatitis C virus (HCV) worldwide. Approximately 30%-50% of patients respond to interferon/ribavirin combination therapy. Response to interferon therapy depends mainly on viral and host genetic factors. The HCV is continually mutating which allows the virus to evade the immune system and overcome interferon treatment. </p>